Posted by Michael Wonder on 26 Feb 2022
Highlights from CHMP 21-24 February 2022 meeting
25 February 2022 - EMA’s CHMP recommended thirteen medicines for approval at its February 2022 meeting.
The CHMP gave a positive opinion for Kimmtrak (tebentafusp) for the treatment of uveal melanoma, a type of eye cancer. Kimmtrak was reviewed under EMA’s accelerated assessment programme.
